Cancer Diagnostic Test Articles & Analysis
7 news found
(NASDAQ: EXAS), a global leader in cancer diagnostics, today announced the presentation of new data at the 2021 San Antonio Breast Cancer Symposium (SABCS) supporting the clinical value of the Oncotype DX Breast Recurrence Score test. ...
About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimize cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score ...
About the Oncotype DX and Oncotype MAP Portfolio of Tests The Oncotype DX portfolio of breast, colon and prostate cancer tests applies advanced genomic science to reveal the unique biology of a tumour in order to optimise cancer treatment decisions. In breast cancer, the Oncotype DX Breast Recurrence Score ...
Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the early detection of cancers, announced today that it has received FDA Breakthrough Device Designation for the IsoPSA® Assay, a novel prostate cancer diagnostic ...
Cancer Diagnostics Services: Our initial cancer diagnostic services test, the LuCED® lung test, has been developed to support the early detection of lung cancer. ...
Cleveland Diagnostics, Inc., a biotechnology company focused on developing next-generation diagnostics for the detection of cancers, today announced the online publication of interim results for an ongoing multi-center trial of the IsoPSA™ prostate cancer test in European Urology. ...
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced a collaboration with Merck & Co., Inc. (known as MSD outside the United States and Canada, through an affiliate) to develop a companion diagnostic test for the analysis of the potential tumor biomarker PD-L1 to aid in the ...